|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CFAP97 |
Gene summary for CFAP97 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CFAP97 | Gene ID | 57587 |
| Gene name | cilia and flagella associated protein 97 | |
| Gene Alias | KIAA1430 | |
| Cytomap | 4q35.1 | |
| Gene Type | protein-coding | GO ID | NA | UniProtAcc | Q9P2B7 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 57587 | CFAP97 | LZE2T | Human | Esophagus | ESCC | 1.15e-05 | 3.65e-01 | 0.082 |
| 57587 | CFAP97 | LZE3D | Human | Esophagus | HGIN | 2.59e-03 | 4.84e-01 | 0.0668 |
| 57587 | CFAP97 | LZE4T | Human | Esophagus | ESCC | 2.52e-14 | 5.15e-01 | 0.0811 |
| 57587 | CFAP97 | LZE7T | Human | Esophagus | ESCC | 2.06e-04 | 1.83e-01 | 0.0667 |
| 57587 | CFAP97 | LZE8T | Human | Esophagus | ESCC | 3.45e-04 | 7.77e-02 | 0.067 |
| 57587 | CFAP97 | LZE22T | Human | Esophagus | ESCC | 1.21e-03 | 1.51e-01 | 0.068 |
| 57587 | CFAP97 | LZE24T | Human | Esophagus | ESCC | 3.98e-08 | 2.54e-01 | 0.0596 |
| 57587 | CFAP97 | LZE21T | Human | Esophagus | ESCC | 8.25e-03 | 1.99e-01 | 0.0655 |
| 57587 | CFAP97 | P1T-E | Human | Esophagus | ESCC | 2.55e-07 | 4.25e-01 | 0.0875 |
| 57587 | CFAP97 | P2T-E | Human | Esophagus | ESCC | 5.86e-45 | 9.35e-01 | 0.1177 |
| 57587 | CFAP97 | P4T-E | Human | Esophagus | ESCC | 1.30e-27 | 6.94e-01 | 0.1323 |
| 57587 | CFAP97 | P5T-E | Human | Esophagus | ESCC | 1.22e-23 | 5.76e-01 | 0.1327 |
| 57587 | CFAP97 | P8T-E | Human | Esophagus | ESCC | 2.76e-18 | 3.51e-01 | 0.0889 |
| 57587 | CFAP97 | P9T-E | Human | Esophagus | ESCC | 8.91e-13 | 3.62e-01 | 0.1131 |
| 57587 | CFAP97 | P10T-E | Human | Esophagus | ESCC | 8.79e-17 | 3.79e-01 | 0.116 |
| 57587 | CFAP97 | P11T-E | Human | Esophagus | ESCC | 5.60e-15 | 3.65e-01 | 0.1426 |
| 57587 | CFAP97 | P12T-E | Human | Esophagus | ESCC | 2.08e-31 | 7.46e-01 | 0.1122 |
| 57587 | CFAP97 | P15T-E | Human | Esophagus | ESCC | 1.52e-23 | 4.78e-01 | 0.1149 |
| 57587 | CFAP97 | P16T-E | Human | Esophagus | ESCC | 5.84e-45 | 8.82e-01 | 0.1153 |
| 57587 | CFAP97 | P17T-E | Human | Esophagus | ESCC | 9.88e-05 | 3.28e-01 | 0.1278 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CFAP97 | SNV | Missense_Mutation | rs781085964 | c.1205C>T | p.Ala402Val | p.A402V | Q9P2B7 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| CFAP97 | SNV | Missense_Mutation | c.615N>T | p.Lys205Asn | p.K205N | Q9P2B7 | protein_coding | tolerated(0.32) | benign(0.001) | TCGA-D8-A27W-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicine+cyclophosphamide | SD | |
| CFAP97 | SNV | Missense_Mutation | c.608N>T | p.Ser203Leu | p.S203L | Q9P2B7 | protein_coding | tolerated(0.1) | benign(0.036) | TCGA-E2-A14V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | |
| CFAP97 | insertion | Nonsense_Mutation | novel | c.825_826insCATTCCCAACAATAAAAAATATCTACTA | p.Asp276HisfsTer5 | p.D276Hfs*5 | Q9P2B7 | protein_coding | TCGA-AR-A0U0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| CFAP97 | SNV | Missense_Mutation | rs373566490 | c.158N>T | p.Ser53Leu | p.S53L | Q9P2B7 | protein_coding | tolerated(0.61) | benign(0) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| CFAP97 | SNV | Missense_Mutation | rs777547282 | c.1397N>A | p.Arg466His | p.R466H | Q9P2B7 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-AA-3672-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| CFAP97 | SNV | Missense_Mutation | c.775N>C | p.Ser259Pro | p.S259P | Q9P2B7 | protein_coding | deleterious(0) | probably_damaging(0.95) | TCGA-AA-3672-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| CFAP97 | SNV | Missense_Mutation | c.53N>G | p.Asp18Gly | p.D18G | Q9P2B7 | protein_coding | deleterious(0) | probably_damaging(0.984) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
| CFAP97 | SNV | Missense_Mutation | novel | c.1069N>A | p.Asp357Asn | p.D357N | Q9P2B7 | protein_coding | tolerated(0.11) | probably_damaging(0.911) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| CFAP97 | SNV | Missense_Mutation | novel | c.495N>T | p.Lys165Asn | p.K165N | Q9P2B7 | protein_coding | deleterious(0.01) | benign(0.071) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |